Literature DB >> 27080944

Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice.

Jinhui Zhang1, Li Li1, Suni Tang2, Yong Zhang2, Maciej Markiewski3, Chengguo Xing4, Cheng Jiang5, Junxuan Lü5.   

Abstract

Herbal products containing Korean Angelica gigas Nakai (AGN) root extract are marketed as dietary supplements for memory enhancement, pain killing, and female menopausal symptom relief. We have shown the anticancer activities of AGN supplements in mouse models. To facilitate human anticancer translational research, we characterized the tissue distribution of AGN marker pyranocoumarin compounds decursin (D) and decursinol angelate (DA) ([Formula: see text]% in AGN) and their metabolite decursinol (DOH), assessed the safety of sub-chronic AGN dietary exposure in mice, and explored its impact on plasma aqueous metabolites and the prostate transcriptome. The data show that after a gavage dose, plasma contained readily detectable DOH, but little D and DA, mirroring patterns in the liver. Extra-hepatic tissues retained greater levels of DA and D than the liver did. For sub-chronic exposures, male mice were provided ad libitum AIN93M-pellet diets with 0.5 and 1% AGN for six weeks. No adverse effects were observed on the plasma biochemistry markers of liver and kidney integrity in spite of their enlargement. Histopathological examinations of the liver, kidney and other visceral organs did not reveal tissue abnormalities. Metabolomic assessment of plasma from mice fed the 1%-AGN diet suggested metabolic shifts of key amino acids especially in the methionine-cysteine cycle, purine cycle, and glycolysis-citrate cycle. Prostate transcriptomic profiling identified gene signature changes in the metabolisms of drugs, lipids and cellular energetics, neuro-muscular features, immunity and inflammation, and tumor suppressor/oncogene balance. The safety profile was corroborated with a daily [Formula: see text] injection of AGN extract (100-300[Formula: see text]mg/kg) for four weeks, which resulted in much greater systemic pyranocoumarin exposure than the dietary route did.

Entities:  

Keywords:  Angelica gigas Nakai; Decursin; Decursinol; Decursinol Angelate; Plasma Metabolome; Safety Assessment; Tissue Distribution

Mesh:

Substances:

Year:  2016        PMID: 27080944      PMCID: PMC4872389          DOI: 10.1142/S0192415X16500191

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  33 in total

1.  In vitro metabolism of pyranocoumarin isomers decursin and decursinol angelate by liver microsomes from man and rodents.

Authors:  Li Li; Jinhui Zhang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Planta Med       Date:  2013-09-11       Impact factor: 3.352

Review 2.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.

Authors:  Albert Chang; Bo-Yeon Kwak; Kwontaek Yi; Jae Soo Kim
Journal:  Phytother Res       Date:  2011-09-02       Impact factor: 5.878

4.  Safety evaluation of Angelica gigas: Genotoxicity and 13-weeks oral subchronic toxicity in rats.

Authors:  Jun-Won Yun; Jeong-Hwan Che; Euna Kwon; Yun-Soon Kim; Seung-Hyun Kim; Ji-Ran You; Woo Ho Kim; Hyeon Hoe Kim; Byeong-Cheol Kang
Journal:  Regul Toxicol Pharmacol       Date:  2015-05-29       Impact factor: 3.271

5.  Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Authors:  Daniel C Danila; Aseem Anand; Nikolaus Schultz; Glenn Heller; Mingliang Wan; Clifford C Sung; Charles Dai; Raya Khanin; Martin Fleisher; Hans Lilja; Howard I Scher
Journal:  Eur Urol       Date:  2013-07-26       Impact factor: 20.096

6.  Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations.

Authors:  Junxuan Lü; Jinhui Zhang; Li Li; Cheng Jiang; Chengguo Xing
Journal:  Curr Pharmacol Rep       Date:  2015-04-19

7.  Nupr1: the Swiss-knife of cancer.

Authors:  Carla E Cano; Tewfik Hamidi; Maria José Sandi; Juan L Iovanna
Journal:  J Cell Physiol       Date:  2011-06       Impact factor: 6.384

8.  Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA.

Authors:  Atanas Kamburov; Rachel Cavill; Timothy M D Ebbels; Ralf Herwig; Hector C Keun
Journal:  Bioinformatics       Date:  2011-09-04       Impact factor: 6.937

9.  Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats.

Authors:  Li Li; Jinhui Zhang; Chengguo Xing; Sung-Hoon Kim; Junxuan Lü
Journal:  Planta Med       Date:  2013-01-30       Impact factor: 3.352

10.  Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Authors:  J L L Robinson; T E Hickey; A Y Warren; S L Vowler; T Carroll; A D Lamb; N Papoutsoglou; D E Neal; W D Tilley; J S Carroll
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

View more
  2 in total

1.  Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.

Authors:  Wei Wu; Su-Ni Tang; Yong Zhang; Manohar Puppala; Timothy K Cooper; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2017-11-09       Impact factor: 4.667

Review 2.  The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.

Authors:  Eleazer P Resurreccion; Ka-Wing Fong
Journal:  Metabolites       Date:  2022-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.